CDK8/19 inhibition overcomes in vitro and in vivo resistance to lapatinib in HER2+breast cancer via STAT1 and STAT3.

被引：0
|
作者：
Ding, Xiaokai [1 ]
Sharko, Amanda C. [1 ]
McDermott, Martina S-J [1 ]
Ji, Hao [1 ]
Chumanevich, Alexander [1 ]
Schools, Gary P. [1 ]
Mack, Zachary T. [1 ]
Pugacheva, Elena [2 ]
Tatarskiy, Victor [3 ]
Khrustaleva, Anastasia [3 ]
Tyakht, Alexander [3 ]
Shtutman, Michael [1 ]
Chen, Mengqian [4 ]
Roninson, Igor [1 ]
Broude, Eugenia V. [1 ]
机构：
[1] Univ South Carolina, Coll Pharm, Columbia, SC 29208 USA
[2] West Virginia Univ, Sch Med, Morgantown, WV 26506 USA
[3] Russian Acad Sci, Inst Gene Biol, Moscow, Russia
[4] Senex Biotechnol, Columbia, SC USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB132
引用
收藏
页数：2
相关论文
共 50 条
  • [31] IFN-β-mediated inhibition of IL-8 expression requires the ISGF3 components Stat1, Stat2, and IRF-9
    Laver, Travis
    Nozell, Susan E.
    Benveniste, Etty N.
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2008, 28 (01): : 13 - 23
  • [32] Constitutively activated STAT3 is predictive for trastuzumab resistance in primary HER2 positive breast cancer
    Sonnenblick, A.
    Brohee, S.
    Salgado, R. F.
    Van den Eynden, G.
    Neven, P.
    Loibl, S.
    Denkert, C.
    Joensuu, H.
    Piccart, M.
    Sotiriou, C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [33] Cancer upregulated gene 2, a novel oncogene, enhances migration and drug resistance of colon cancer cells via STAT1 activation
    Malilas, Waraporn
    Koh, Sang Seok
    Kim, Seokho
    Srisuttee, Ratakorn
    Cho, Il-Rae
    Moon, Jeong
    Yoo, Hwa-Seung
    Oh, Sangtaek
    Johnston, Randal N.
    Chung, Young-Hwa
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 43 (04) : 1111 - 1116
  • [34] Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: Structural recognition of STAT SH2 domains (vol 17, pg 1875, 2007)
    Gunning, Patrick T.
    Katt, William P.
    Glenn, Matthew
    Siddiquee, Khandaker
    Kim, Joon S.
    Jove, Richard
    Sebti, Said M.
    Turkson, James
    Hamilton, Andrew D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (10) : 2949 - 2949
  • [35] YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cells
    Fujii, Teruhiko
    Seki, Naoko
    Namoto-Matsubayashi, Roka
    Takahashi, Hiroki
    Inoue, Yuka
    Toh, Uhi
    Kage, Masayoshi
    Shirouzu, Kazuo
    FUTURE ONCOLOGY, 2009, 5 (02) : 153 - 156
  • [36] CDK12 inhibition enhances sensitivity of HER2+breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT
    Li, Hui
    Wang, Jinsong
    Yi, Zongbi
    Li, Chunxiao
    Wang, Haijuan
    Zhang, Jingyao
    Wang, Ting
    Nan, Peng
    Lin, Feng
    Xu, Dongkui
    Qian, Haili
    Ma, Fei
    EUROPEAN JOURNAL OF CANCER, 2021, 145 : 92 - 108
  • [37] Niclosamide reverses cisplatin resistance by inhibiting Bcl-2 and Stat3 in HER2-positive breast cancer
    Liu, Junjun
    CANCER RESEARCH, 2021, 81 (04)
  • [38] Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma
    Saraswati, Sarita
    Alhaider, Abdulqader
    Abdelgadir, Abdelgalil Mohamed
    Tanwer, Pooja
    Korashy, Hesham M.
    CELL COMMUNICATION AND SIGNALING, 2019, 17 (01)
  • [39] Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1–mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma
    Sarita Saraswati
    Abdulqader Alhaider
    Abdelgalil Mohamed Abdelgadir
    Pooja Tanwer
    Hesham M. Korashy
    Cell Communication and Signaling, 17
  • [40] Histone deacetylase (HDAC) 6 inhibition potentiates the cytotoxicity of lapatinib and PI3K inhibitors on Her2+breast cancer cell lines.
    Yang, Min
    Tamang, David
    Jones, Simon
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345